FMP
Replimune Group, Inc.
REPL
NASDAQ
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
10.14 USD
-0.22 (-2.17%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
15.19M
8.59M
24.89M
12.31M
11.02M
-
-
-
-
-
6.43k
2.35k
4.36k
9.19k
100
100
100
100
100
278k
255k
183k
246k
-
-
-
-
-
-
117.8
69.86
32.05
183.58
100
80.38
80.38
80.38
80.38
76k
-93k
-
-294k
-
-
-
-
-
-
32.2
-25.48
-
-219.4
100
1.34
1.34
1.34
1.34
334k
164k
166k
17k
83k
-
-
-
-
-
141.53
44.93
29.07
12.69
100
57.34
57.34
57.34
57.34
-40k
-53k
-17k
-47k
-17k
-
-
-
-
-
-16.95
-14.52
-2.98
-35.07
100
-13.9
-13.9
-13.9
-13.9